Endometrial Cancer Prevention, Early Diagnosis and Treatment: Advances and Challenges

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 1357

Special Issue Editor


E-Mail Website
Guest Editor
Division of Cancer Sciences, The University of Manchester, Manchester, UK
Interests: endometrial cancer; surgery; advanced therapy; molecular classification; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The rising global incidence of endometrial cancer means that more women than ever are living with and, unfortunately, also dying from this disease. Whilst surgery in combination with radio- and chemotherapy has long been the cornerstone of endometrial cancer treatment, increasing knowledge of endometrial cancer biology has ensured the success of fertility-sparing approaches and enabled the personalisation of care. The molecular characterisation of tumours and clinical trials of immunotherapies are set to revolutionise how we manage the disease as we move towards improving disease control whilst minimising the side effects of treatment. 

This Special Issue aims to highlight recent advances in the prevention, early diagnosis, and treatment of early and advanced/recurrent endometrial cancer and to answer any outstanding research questions. Both original research articles and review papers are welcome to be submitted to this Special Issue. 

Dr. Sarah J. Kitson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • gynaecologic oncology
  • surgery
  • prevention
  • early diagnosis
  • advanced therapy
  • molecular classification
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 813 KiB  
Article
Patterns and Frequency of Pathogenic Germline Mutations among Patients with Newly-Diagnosed Endometrial Cancer: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) Endometrial Study
by Hikmat Abdel-Razeq, Hira Bani Hani, Baha Sharaf, Faris Tamimi, Hanan Khalil, Areej Abu Sheikha, Mais Alkyam, Sarah Abdel-Razeq, Tala Ghatasheh, Tala Radaideh and Suhaib Khater
Cancers 2024, 16(14), 2543; https://doi.org/10.3390/cancers16142543 - 15 Jul 2024
Viewed by 1126
Abstract
Most of endometrial cancers are sporadic, with 5% or less being attributed to inherited pathogenic germline mutations and mostly related to the Lynch syndrome. To our knowledge, this is the first study to investigate patterns and frequencies of germline mutations in patients with [...] Read more.
Most of endometrial cancers are sporadic, with 5% or less being attributed to inherited pathogenic germline mutations and mostly related to the Lynch syndrome. To our knowledge, this is the first study to investigate patterns and frequencies of germline mutations in patients with endometrial cancer in an Arab region. Consecutive patients with endometrial cancer (n = 130), regardless of their age and family history, were enrolled. Germline genetic testing, using an 84-gene panel, was performed on all. Almost half of the patient population (n = 64, 49.2%) was tested based on international guidelines, while the remaining patients (n = 66, 50.8%) were tested as part of an ongoing universal germline genetic testing program. Among the whole group, 18 (13.8%) patients had positive pathogenic or likely pathogenic (P/LP) germline variants. The most common variants encountered were in MLH1 (n = 4, 22.2%), PMS2 (n = 3, 16.7%), ATM, MSH2, MUTYH, and BRCA2 (n = 2, 11.1% each). In addition, three (2.3%) patients were found to have an increased risk allele of the APC gene. P/LP variants were more common among patients with carcinosarcoma and clear cell carcinoma, younger patients (age ≤ 50 years), and in patients with a non-metastatic disease. We conclude that germline genetic variants, mostly in genes related to the Lynch syndrome, are relatively common among Arab patients with endometrial cancer. Full article
Show Figures

Figure 1

Back to TopTop